Is CNTX or OTLK more profitable?

Oncobiologics' return on equity of 0.00% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -82.06% -72.74% Oncobiologics N/A N/A -291.28%

Does the media refer more to CNTX or OTLK?

In the previous week, Oncobiologics had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 13 mentions for Oncobiologics and 11 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.51 beat Oncobiologics' score of 0.37 indicating that Context Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncobiologics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CRBU or CNTX?

In the previous week, Context Therapeutics had 3 more articles in the media than Caribou Biosciences. MarketBeat recorded 11 mentions for Context Therapeutics and 8 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.55 beat Context Therapeutics' score of 0.51 indicating that Caribou Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caribou Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Context Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, NKTX or CNTX?

Nkarta is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nkarta N/A N/A -$104.08M -$1.57 N/A Context Therapeutics N/A N/A -$36.12M -$0.48 N/A

Is NKTX or CNTX more profitable?

Nkarta's return on equity of -39.64% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -39.64% -30.45% Context Therapeutics N/A -82.06% -72.74%

Does the media favor NKTX or CNTX?

In the previous week, Nkarta had 7 more articles in the media than Context Therapeutics. MarketBeat recorded 18 mentions for Nkarta and 11 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.51 beat Nkarta's score of -0.14 indicating that Context Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nkarta 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Context Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MOLN or CNTX more profitable?

Molecular Partners' return on equity of -66.62% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Molecular Partners N/A -66.62% -54.85% Context Therapeutics N/A -82.06% -72.74%

Which has stronger earnings & valuation, CNTX or OKUR?

OnKure Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Context Therapeutics N/A N/A -$36.12M -$0.48 N/A OnKure Therapeutics N/A N/A -$59.52M -$3.50 N/A

Is CNTX or OKUR more profitable?

OnKure Therapeutics' return on equity of -49.01% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -82.06% -72.74% OnKure Therapeutics N/A -49.01% -45.77%

Context Therapeutics (CNTX) Competitors

$0.52 +0.02 (+3.26%)

Closing price 04:00 PM Eastern

Extended Trading

$0.52 0.00 (-0.94%)

As of 07:25 PM Eastern

Compare

CNTX vs. OTLK, CRBU, NKTX, MOLN, and OKUR

Should you buy Context Therapeutics stock or one of its competitors? Context Therapeutics's main competitors and comparable companies include Oncobiologics (OTLK), Caribou Biosciences (CRBU), Nkarta (NKTX), Molecular Partners (MOLN), and OnKure Therapeutics (OKUR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Context Therapeutics compare to Oncobiologics?

Context Therapeutics (NASDAQ:CNTX) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Context Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market.

Context Therapeutics has higher earnings, but lower revenue than Oncobiologics. Context Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
Oncobiologics	$1.35M	83.25	-$62.42M	-$1.17	N/A

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Context Therapeutics presently has a consensus target price of $6.17, suggesting a potential upside of 1,079.32%. Oncobiologics has a consensus target price of $4.65, suggesting a potential upside of 514.75%. Given Context Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Context Therapeutics is more favorable than Oncobiologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Oncobiologics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Oncobiologics' return on equity of 0.00% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
Oncobiologics	N/A	N/A	-291.28%

In the previous week, Oncobiologics had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 13 mentions for Oncobiologics and 11 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.51 beat Oncobiologics' score of 0.37 indicating that Context Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncobiologics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Context Therapeutics beats Oncobiologics on 10 of the 14 factors compared between the two stocks.

How does Context Therapeutics compare to Caribou Biosciences?

Caribou Biosciences (NASDAQ:CRBU) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Context Therapeutics has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,030.42%. Context Therapeutics' return on equity of -82.06% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,030.42%	-84.75%	-59.73%
Context Therapeutics	N/A	-82.06%	-72.74%

Caribou Biosciences has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market.

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by company insiders. Comparatively, 4.8% of Context Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Caribou Biosciences presently has a consensus target price of $7.75, suggesting a potential upside of 390.51%. Context Therapeutics has a consensus target price of $6.17, suggesting a potential upside of 1,079.32%. Given Context Therapeutics' higher possible upside, analysts clearly believe Context Therapeutics is more favorable than Caribou Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Context Therapeutics has lower revenue, but higher earnings than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16M	14.04	-$148.12M	-$1.42	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

In the previous week, Context Therapeutics had 3 more articles in the media than Caribou Biosciences. MarketBeat recorded 11 mentions for Context Therapeutics and 8 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.55 beat Context Therapeutics' score of 0.51 indicating that Caribou Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caribou Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Context Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Caribou Biosciences and Context Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Context Therapeutics compare to Nkarta?

Nkarta (NASDAQ:NKTX) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

In the previous week, Nkarta had 7 more articles in the media than Context Therapeutics. MarketBeat recorded 18 mentions for Nkarta and 11 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.51 beat Nkarta's score of -0.14 indicating that Context Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nkarta	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Context Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nkarta's return on equity of -39.64% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-39.64%	-30.45%
Context Therapeutics	N/A	-82.06%	-72.74%

Nkarta currently has a consensus price target of $11.20, suggesting a potential upside of 380.69%. Context Therapeutics has a consensus price target of $6.17, suggesting a potential upside of 1,079.32%. Given Context Therapeutics' higher possible upside, analysts clearly believe Context Therapeutics is more favorable than Nkarta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 9.8% of Nkarta shares are owned by insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Nkarta is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

Nkarta has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market.

Summary

Nkarta and Context Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Context Therapeutics compare to Molecular Partners?

Molecular Partners (NASDAQ:MOLN) and Context Therapeutics (NASDAQ:CNTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

26.6% of Molecular Partners shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by company insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Molecular Partners presently has a consensus price target of $8.38, suggesting a potential upside of 104.02%. Context Therapeutics has a consensus price target of $6.17, suggesting a potential upside of 1,079.32%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Context Therapeutics is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Molecular Partners has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market.

In the previous week, Context Therapeutics had 9 more articles in the media than Molecular Partners. MarketBeat recorded 11 mentions for Context Therapeutics and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 1.43 beat Context Therapeutics' score of 0.51 indicating that Molecular Partners is being referred to more favorably in the media.

Company	Overall Sentiment
Molecular Partners	Positive
Context Therapeutics	Positive

Context Therapeutics has lower revenue, but higher earnings than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	29.34	-$74.41M	-$1.94	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A

Molecular Partners' return on equity of -66.62% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
Context Therapeutics	N/A	-82.06%	-72.74%

Summary

Context Therapeutics beats Molecular Partners on 8 of the 14 factors compared between the two stocks.

How does Context Therapeutics compare to OnKure Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

Context Therapeutics presently has a consensus price target of $6.17, indicating a potential upside of 1,079.32%. OnKure Therapeutics has a consensus price target of $17.50, indicating a potential upside of 338.60%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Context Therapeutics is more favorable than OnKure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Context Therapeutics has a beta of 1.74, suggesting that its stock price is 74% more volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

OnKure Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by company insiders. Comparatively, 2.2% of OnKure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Context Therapeutics had 10 more articles in the media than OnKure Therapeutics. MarketBeat recorded 11 mentions for Context Therapeutics and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.87 beat Context Therapeutics' score of 0.51 indicating that OnKure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Context Therapeutics	Positive
OnKure Therapeutics	Very Positive

OnKure Therapeutics' return on equity of -49.01% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
OnKure Therapeutics	N/A	-49.01%	-45.77%

Summary

Context Therapeutics beats OnKure Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Context Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTX vs. The Competition

Export

Metric	Context Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$46.53M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-1.09	6.29	211.09	21.74
Price / Sales	N/A	1,295.89	602.98	92.99
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	1.25	16.78	12.91	6.24
Net Income	-$36.12M	-$13.32M	$3.45B	$347.60M
7 Day Performance	8.04%	1.74%	1.12%	1.07%
1 Month Performance	-16.05%	1.60%	1.79%	1.03%
1 Year Performance	-28.98%	56.43%	67.69%	20.77%

Context Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTX Context Therapeutics	2.9588 of 5 stars	$0.52 +3.3%	$6.17 +1,079.3%	-27.7%	$46.53M	N/A	N/A	7
OTLK Oncobiologics	3.587 of 5 stars	$1.14 -1.3%	$4.65 +309.7%	-58.3%	$167.16M	$1.35M	N/A	20	News Coverage Earnings Report Analyst Upgrade Short Interest Increase Gap Down
CRBU Caribou Biosciences	2.2102 of 5 stars	$1.69 +1.5%	$8.67 +414.3%	-17.4%	$167.12M	$11.16M	N/A	100	News Coverage Earnings Report Analyst Forecast
NKTX Nkarta	3.0901 of 5 stars	$2.33 -5.3%	$11.40 +389.3%	+4.1%	$167.05M	N/A	N/A	140	Trending News Earnings Report Analyst Forecast Analyst Revision Gap Down
MOLN Molecular Partners	3.2281 of 5 stars	$4.12 -0.2%	$8.38 +103.2%	+10.2%	$166.41M	$5.65M	N/A	180	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Context Therapeutics (CNTX) Competitors

CNTX vs. OTLK, CRBU, NKTX, MOLN, and OKUR

How does Context Therapeutics compare to Oncobiologics?

Summary

How does Context Therapeutics compare to Caribou Biosciences?

Summary

How does Context Therapeutics compare to Nkarta?

Summary

How does Context Therapeutics compare to Molecular Partners?

Summary

How does Context Therapeutics compare to OnKure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX vs. The Competition

Context Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Context Therapeutics (CNTX) Competitors

CNTX vs. OTLK, CRBU, NKTX, MOLN, and OKUR

How does Context Therapeutics compare to Oncobiologics?

Which has more risk and volatility, CNTX or OTLK?

Which has preferable valuation & earnings, CNTX or OTLK?

Do insiders & institutionals hold more shares of CNTX or OTLK?

Do analysts rate CNTX or OTLK?

Is CNTX or OTLK more profitable?

Does the media refer more to CNTX or OTLK?

Summary

How does Context Therapeutics compare to Caribou Biosciences?

Is CRBU or CNTX more profitable?

Which has more volatility and risk, CRBU or CNTX?

Do institutionals & insiders believe in CRBU or CNTX?

Do analysts rate CRBU or CNTX?

Which has better valuation & earnings, CRBU or CNTX?

Does the media favor CRBU or CNTX?

Summary

How does Context Therapeutics compare to Nkarta?

Does the media favor NKTX or CNTX?

Is NKTX or CNTX more profitable?

Do analysts recommend NKTX or CNTX?

Do institutionals and insiders hold more shares of NKTX or CNTX?

Which has higher earnings & valuation, NKTX or CNTX?

Which has more risk and volatility, NKTX or CNTX?

Summary

How does Context Therapeutics compare to Molecular Partners?

Do institutionals & insiders hold more shares of MOLN or CNTX?

Do analysts rate MOLN or CNTX?

Which has more risk and volatility, MOLN or CNTX?

Does the media favor MOLN or CNTX?

Which has better earnings and valuation, MOLN or CNTX?

Is MOLN or CNTX more profitable?

Summary

How does Context Therapeutics compare to OnKure Therapeutics?

Do analysts prefer CNTX or OKUR?

Which has more risk and volatility, CNTX or OKUR?

Which has stronger earnings & valuation, CNTX or OKUR?

Do insiders and institutionals have more ownership in CNTX or OKUR?

Does the media refer more to CNTX or OKUR?

Is CNTX or OKUR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX vs. The Competition

Context Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools